Including Funding rounds, Bull / Bear thesis, Stock + earnings, Roster changes, Patents, News, and Open roles.
Already subscribed? Sign in →
Professor of Electrical and Computer Engineering at Rice University with a Ph.D. in Applied Physics from Cornell and a postdoctoral fellowship at Harvard focused on BCI and bioelectronics. He spent 12 years at Rice leading a lab that published over 60 peer-reviewed articles in Nature, Science, and Nature Biomedical Engineering, and secured over $40 million in federal funding, including multiple DARPA neurotech grants. He founded Motif Neurotech in 2022 to commercialise the DOT (Digitally programmable Over-brain Therapeutic) — a blueberry-sized device that sits in the skull above the dura without touching the brain, targeting mood and cognitive disorders.
AI bull / bear analysis hasn’t been generated for this company yet. Cases refresh quarterly using the latest classified articles and funding history.
No articles ingested yet for Motif Neurotech. Once the hourly news pipeline is live, every article the classifier tags as mentioning this company appears here with its one-line AI summary and sentiment.
A pea-sized (~9 mm) minimally-invasive cortical neurostimulator implanted via a brief outpatient procedure to treat treatment-resistant depression. Pairs wirelessly with a wearable hat that delivers prescribed stimulation sessions at home. Uses magnetoelectric energy transfer derived from Rice University IP, avoiding the large external magnets required by TMS while targeting specific cortical regions.
An investigational deep-brain modulation implant targeting subcortical structures associated with mood regulation, developed under FDA Investigational Device Exemption for treatment-resistant depression. Designed to deliver closed-loop electrical stimulation with sensing capabilities to personalize therapy based on detected neural biomarkers.